Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy - PubMed
6 hours ago
- #PAR-2 inhibitor
- #anti-PD-mA1 immunotherapy
- #antigen presentation
- High PAR-2 activation in cancer patient serum correlates with worse survival after immunotherapy.
- Inhibiting PAR-2 genetically or pharmacologically boosts anti-PD-1 therapy in preclinical models.
- PAR-2 blockade reduces immunosuppressive myeloid cells and enhances CD8+ T cell activation.
- PAR-2 inhibition shifts cytokines toward Th1-type responses and away from immunosuppression.
- Myeloid cell RNA sequencing shows PAR-2 impairs antigen presentation pathways.
- Ex vivo, PAR-2 inhibition improves antigen presentation by CD11c+ dendritic cells.
- PAR-2 targeting is a promising strategy to overcome resistance to immune checkpoint inhibitors.